GlassScriptPhysician profile
Wayne Russell Bonlie
NPI 1093770042
$3,110.98
in general payments reported to CMS, 2019-2025
29 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $177 · 2021: $295 · 2022: $630 · 2023: $769 · 2024: $473 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.01 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Lilly USA, LLC | $321.03 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.86 | 2019-2023 | Xifaxan, Trulance |
| Acella Pharmaceuticals, LLC | $253.54 | 2022-2025 | NP Thyroid 60 |
| Paratek Pharmaceuticals, INC. | $227.51 | 2022-2025 | Nuzyra |
| Ibsa Pharma INC. | $210.22 | 2019-2024 | Tirosint, Licart, Tirosint |
| Csl Behring | $178.40 | 2023-2025 | Hizentra |
| Scynexis, INC. | $160.42 | 2022 | |
| Eisai INC. | $100.74 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $99.63 | 2024-2025 | Keveyis |
| Vyera Pharmaceuticals, LLC | $87.06 | 2020-2022 | |
| Grifols USA, LLC | $71.50 | 2023-2025 | Xembify, Gamunex-C |
| Qol Medical, LLC | $68.97 | 2022-2023 | Sucraid |
| Romark Laboratories, Lc | $60.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.31 | 2021-2024 | Dificid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $41.77 | 2024-2025 | Voquezna |
| Mycovia Pharmaceuticals, INC. | $36.65 | 2022-2023 | Vivjoa |
| Lupin INC. | $31.55 | 2019 | |
| Fidia Pharma USA INC. | $26.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.68 | 2020-2021 | |
| Exact Sciences Corporation | $22.04 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $21.84 | 2025 | Quviviq |
| Bio Products Laboratory USA, INC. | $20.84 | 2021 | |
| Dexcom, INC. | $20.64 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $18.75 | 2019 | |
| Abbott Laboratories | $17.50 | 2023 | Proclaim |
| Horizon Therapeutics Plc | $17.46 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.59 | 2019 | |
| Pfizer INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Bonlie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.